Found: 14
Select item for more details and to access through your institution.
Apremilast Ameliorates Experimental Arthritis <italic>via</italic> Suppression of Th1 and Th17 Cells and Enhancement of CD4<sup>+</sup>Foxp3<sup>+</sup> Regulatory T Cells Differentiation.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.01662
- By:
- Publication type:
- Article
Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
- Published in:
- British Journal of Haematology, 2013, v. 160, n. 4, p. 487, doi. 10.1111/bjh.12172
- By:
- Publication type:
- Article
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
- Published in:
- British Journal of Haematology, 2011, v. 154, n. 3, p. 325, doi. 10.1111/j.1365-2141.2011.08689.x
- By:
- Publication type:
- Article
Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory <i>KRAS</i>-Mutant Metastatic Colorectal Cancer Patients.
- Published in:
- PLoS ONE, 2013, v. 8, n. 11, p. 1, doi. 10.1371/journal.pone.0080437
- By:
- Publication type:
- Article
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4 <sup>CRBN</sup>.
- Published in:
- British Journal of Haematology, 2014, v. 164, n. 6, p. 811, doi. 10.1111/bjh.12708
- By:
- Publication type:
- Article
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.
- Published in:
- British Journal of Haematology, 2014, v. 164, n. 2, p. 233, doi. 10.1111/bjh.12622
- By:
- Publication type:
- Article
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma.
- Published in:
- Journal of Translational Medicine, 2007, v. 5, p. 38, doi. 10.1186/1479-5876-5-38
- By:
- Publication type:
- Article
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study.
- Published in:
- Rheumatology & Therapy, 2020, v. 7, n. 1, p. 101, doi. 10.1007/s40744-019-00182-7
- By:
- Publication type:
- Article
Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice.
- Published in:
- Drugs in R&D, 2019, v. 19, n. 4, p. 329, doi. 10.1007/s40268-019-00284-1
- By:
- Publication type:
- Article
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.
- Published in:
- Arthritis Research & Therapy, 2015, v. 17, n. 1, p. 1, doi. 10.1186/s13075-015-0771-6
- By:
- Publication type:
- Article
Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study.
- Published in:
- Journal of Rheumatology, 2018, v. 45, n. 3, p. 405, doi. 10.3899/jrheum.161040
- By:
- Publication type:
- Article
Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1).
- Published in:
- Journal of Immunology Research, 2015, v. 2015, p. 1, doi. 10.1155/2015/906349
- By:
- Publication type:
- Article
The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).
- Published in:
- 2015
- By:
- Publication type:
- journal article